Jnana Therapeutics is a biotechnology company utilizing a next generation chemoproteomic platform to address well-validated but hard-to-drug targets, including the solute carrier (SLC) family of metabolite transporters. Jnana is focused on developing best-in-class therapies to treat a wide range of diseases, including immune-mediated, neurological and metabolite-dependent diseases. Headquartered in Boston, Jnana is founded by world-renowned scientists and backed by leading life science investors. For more information, please visit www.jnanatx.com and follow us on Twitter and on LinkedIn.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $207M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | RA Capital... | racap.com |
| 16.11.2022 | Bain Capit... | baincapita... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 15.11.2022 | Series C | $107M | - |
| 20.08.2021 | Series B | $50M | - |
| 15.12.2017 | Series A | $50M | - |
Mentions in press and media 13
| Date | Title | Description |
| 07.08.2024 | Healthcare And AI Sectors Continue To Lead, While Funding Settles In July 2024 | 6 Shares Email Facebook Twitter LinkedIn Venture funding reached over $23 billion in July 2024, slightly down month over month and up more than 20% year over year, based on an analysis of Crunchbase data. The largest funding in July went to... |
| 15.11.2022 | Jnana Therapeutics Lands $107M Series C Round | BOSTON, MA, Jnana Therapeutics today announced the close of its $107 million Series C financing. >> Click here for more funding data on Jnana Therapeutics >> To export Jnana Therapeutics funding data to PDF and Excel, click ... |
| 15.11.2022 | Jnana Therapeutics Raises $107M in Series C Funding | Jnana Therapeutics, a Boston, MA-based biotechnology company, raised $107M in Series C funding. The round was led by Bain Capital Life Sciences with participation from existing investors including RA Capital Management, Polaris Partners, Ve... |
| 20.08.2021 | Jnana Therapeutics Closes $50M Series B Financing | Jnana Therapeutics, a Boston, Mass.-based biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but hard-to-drug targets, closed a $50m Series B financing. The round ... |
| 19.08.2021 | Jnana Therapeutics brings in $50M Series B | Jnana Therapeutics has raised $50 million in a round led by RA Capital Management. The Boston-based company's drug discovery platform targets specific transport proteins to address a range of diseases. The company plans to use the funding i... |
| 19.08.2021 | Jnana Therapeutics Closes $50 Million Series B Financing To Advance Lead PKU Program and Small Molecule Pipeline Based On Next Gen Chemoproteomic Platform | – Funds progression of lead program, an oral approach to treating phenylketonuria (PKU), into the clinic – – Supports expanded application of chemoproteomic RAPID platform for small-molecule discovery for hard-to-drug targets – Jnana Therap... |
| 18.08.2021 | Jnana nets $50M to push newly unveiled PKU program, expand into more hard-to-drug targets Age-Appropriate Formulation Development for Pediatric Trials-Challenges and Considerations | After years chasing a hard-to-drug group of targets called solute carriers, Jnana Therapeutics is revealing its lead program and a new $50 million financing to get it into the clinic. RELATED: Roche, Jnana take aim at metabolite transporter... |
| 18.08.2021 | Jnana nets $50M to push newly unveiled PKU program, expand into more hard-to-drug targets | After years chasing a hard-to-drug group of targets called solute carriers, Jnana Therapeutics is revealing its lead program and a new $50 million financing to get it into the clinic. That program targets phenylketonuria (PKU), a rare, inhe... |
| 18.08.2021 | Jnana Therapeutics : Closes $50 Million Series B Financing to Advance Lead PKU Program and Small Molecule Pipeline Based on Next Gen Chemoproteomic Platform | Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but hard-to-drug targets, today announced the closing of a $50 million Series B financing.... |
| 15.12.2017 | Jnana Therapeutics Raises $50M in Series A Financing | Jnana Therapeutics Inc., a Boston, MA-based developer of a drug discovery platform dedicated to targeting the solute carrier (SLC) family of transporters, the cell’s metabolic gates, raised $50m in Series A financing. Backers included Polar... |
Show more